Deferoxamine

Deferoxamine has been studied in 38 papers since 2006: 6 observational studies in people, 23 in animals, 3 in cells, 5 reviews; 14 in the past year. It is an approved medicine. The newest story, Oct 4, 2026: “Silencing LCN2 eases postoperative cognitive deficits in mice”.

InterventionApproved 1968

38 papers study it7 more mention it54 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 122% faster than aging research as a whole: 11 papers in the latest year counted

2 new papers in 30 daysSee all 45 papers on deferoxamine

At a glance

Deferoxamine reduces senescence in rat cells and ferroptosis in mouse cells across independent labs, but a rat study reports increased senescence. Mouse studies from one group report less muscle atrophy in aged mice and improved ovarian reserve in aging mice. A paper declares company ties.

54 findings in 31 papers from 2006 to 2026, 6 of them since May 2026

The findings reach mice, none yet in people; independent labs found the same change in cells. 29 independent labs in 9 countries; 28 trials, none about aging, 11 with no results posted.

2 of its findings point the other way.

Cells: replicated by independent labs. Worms or flies and mice: a single group. Humans: nothing yet.
  • 29 independent labs in 9 countries
  • 2 findings against
  • 28 trials, none about aging, 11 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 2 of 53 findings with company ties
  • Humans6
  • Animals23
  • Cells3
  • In silico1

What did lifespan studies of deferoxamine find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.

What did studies of deferoxamine find?

47

Studies of deferoxamine measured 47 outcomes; the most studied are cellular senescence (4 studies), inflammation (2) and ferroptosis (2).

Cellular senescence

downin cells2downin rat cells1upin rats1

4 studies
  1. Deferoxamine decreases cellular senescence in microglia.

    “Deferoxamine (DFX) mitigated microglial senescence and ferroptosis.”

    Cellsin microgliamicroglia

    27-Hydroxycholesterol triggers microglial senescence subsequent to iron over-loading contributes to brain aging, suppressed by Deferoxamine

    npj aging

  2. Deferoxamine decreases cellular senescence in HG-treated renal cells.

    “The treatment of deferoxamine (0.5 μM) had the opposite effect.”

    Cellsin HG-treated renal cells0.5 μM

    Excess iron accumulation mediated senescence in diabetic kidney injury

    Journal of biochemical and molecular toxicology

  3. Deferoxamine induces cellular senescence in rats.

    “Early EPCs from DFO-treated rats displayed profoundly senescent phenotypes compared to those from control rats.”

    Animals4 weeks

    Deferoxamine accelerates endothelial progenitor cell senescence and compromises angiogenesis

    Aging

  4. Deferoxamine decreases cellular senescence in rat cells (ex vivo BMSCs from aged rats).

    “as well as rejuvenate senescent BMSCs (ROS level and SA-β-gal staining) and revise the expression of stemness/senescence-associated genes”

    Cellsex vivo BMSCs from aged ratsbone marrow stromal cell60 mg/kg daily10 days

    Intraperitoneal injection of Desferal® alleviated the age-related bone loss and senescence of bone marrow stromal cells in rats

    Stem cell research & therapy

More on Cellular senescence

Inflammation

downin mice1downin mouse cells1

2 studies
  1. Deferoxamine inhibits inflammation in mouse cells (BV2 microglia).

    “pharmacological inhibition of the iron-ROS pathway by DFO effectively suppressed LCN2-induced M1 polarization.”

    CellsBV2 microglia

    Silencing LCN2 eases postoperative cognitive deficits in mice

    Research SquarePreprint

  2. Deferoxamine decreases inflammation in mice (nanofat-seeded dermal substitutes).

    “short-term ex vivo DFO pretreatment effectively primes nanofat to enhance microvascular network formation and suppress inflammation”

    Animalsnanofat-seeded dermal substitutesex vivo nanofat pretreatmentperi-implant venules and dermal substitute implants1 mM1 h pretreatment; 14-day assessment

    Short-term pretreatment with deferoxamine enhances the in vivo vascularization capacity of nanofat seeded onto dermal substitutes

    EXCLI journal

More on Inflammation

Ferroptosis

downin mouse cells2

2 studies
  1. Deferoxamine decreases ferroptosis in mouse cells (D-galactose-induced senescent myoblasts).

    “treatment with the iron chelator deferoxamine (DFO) significantly attenuated senescence-associated ferroptosis”

    CellsD-galactose-induced senescent myoblastsmyoblasts

    NCOA4-Mediated Ferritinophagy Contributes to Iron Overload-Driven Ferroptosis of Senescent Myoblasts in Mice

    Cells

  2. Deferoxamine decreases ferroptosis in MLTC-1 cells with increased ferroptosis.

    “Increased levels of ferroptosis in MLTC-1 leads to mitochondria-derived OS and apoptosis, which can be partially restored by deferoxamine and overexpressing SLC7A11.”

    Cellsin MLTC-1 cells with increased ferroptosis

    Peroxiredoxin 4 Involved in Spermatogenesis by Affecting Oxidative Stress and Ferroptosis

    Andrology

More on Ferroptosis

Extracellular matrix remodeling

downin human cells1upin mice1

2 studies
  1. Deferoxamine decreases extracellular matrix remodeling in hASM cells.

    “Iron depletion mitigated the antioxidant response, lipid peroxidation, cell proliferation, and ECM production.”

    Cellsin hASM cells100 μM72 h

    Dysregulated iron metabolism in remodeling of aging asthmatic human airways

    American journal of physiology. Cell physiology

  2. Deferoxamine increases extracellular matrix remodeling in mice (nanofat-seeded dermal substitutes).

    “DFO pretreatment promoted the tissue integration of the implants and regenerative extracellular matrix remodeling, as evidenced by increased collagen III deposition.”

    Animalsnanofat-seeded dermal substitutesex vivo nanofat pretreatmentdermal substitute implants1 mM1 h pretreatment; 14-day assessment

    Short-term pretreatment with deferoxamine enhances the in vivo vascularization capacity of nanofat seeded onto dermal substitutes

    EXCLI journal

More on Extracellular matrix remodeling

Oxidative stress and ROS signaling

downin O. cuniculus1downin worms1

2 studies
  1. Deferoxamine protects against oxidative stress and ROS signaling in alcohol-exposed C. elegans.

    “generated reproductive toxicity and oxidative stress, while rescued by ferroptosis inhibitor Fer-1(100 μmol/L) and iron chelating agent DFO (50 μmol/L)”

    Model organismsin alcohol-exposed C. elegans50 μmol/L

    Exposure to Alcohol Causes Ferroptosis Activation Associated with Suppression of Heat Shock Responses-mediated iron metabolism disorder in Caenorhabditis elegans

    Food Science and Human Wellness

  2. Deferoxamine decreases oxidative stress and ROS signaling in O. cuniculus.

    “in AR deferoxamine lowered myocardial lipid and protein oxidation, and reduced EDP with a tendency to augment CF.”

    Animalsheart0.6mM or 3.6mM

    Iron status and oxidative stress in the aged rabbit heart

    Journal of molecular and cellular cardiology

More on Oxidative stress and ROS signaling

Muscle atrophy

downin mice1

1 study
  1. Deferoxamine decreases muscle atrophy in mice (aged sarcopenia mice).

    “pharmacological inhibition of iron overload or ferroptosis by DFO or ferrostatin-1 (Ferr-1) effectively ameliorated skeletal muscle atrophy and functional decline in aged sarcopenia mice”

    Animalsaged sarcopenia miceskeletal muscle

    NCOA4-Mediated Ferritinophagy Contributes to Iron Overload-Driven Ferroptosis of Senescent Myoblasts in Mice

    Cells

More on Muscle atrophy

Cell proliferation

downin human cells1

1 study
  1. Deferoxamine decreases cell proliferation in hASM cells.

    “Iron depletion mitigated the antioxidant response, lipid peroxidation, cell proliferation, and ECM production.”

    Cellsin hASM cells100 μM72 h

    Dysregulated iron metabolism in remodeling of aging asthmatic human airways

    American journal of physiology. Cell physiology

Iron-induced pathological cascades

downin human cells1

1 study
  1. Deferoxamine decreases iron-induced pathological cascades in human cells (iron overload; ferroptosis and senescence-associated secretory phenotype).

    “Importantly, these pathological cascades were reversible upon treatment with the iron chelator deferoxamine (DFO).”

    Cellsiron overload; ferroptosis and senescence-associated secretory phenotypecorneal stromal cell

    Iron overload triggers pathological remodeling of corneal stroma through ferroptosis and senescence-associated secretory phenotype in keratoconus

    Redox biology

Implant tissue integration

upin mice1

1 study
  1. Deferoxamine improves implant tissue integration in mice (nanofat-seeded dermal substitutes).

    “DFO pretreatment promoted the tissue integration of the implants”

    Animalsnanofat-seeded dermal substitutesex vivo nanofat pretreatmentdermal substitute implants1 mM1 h pretreatment; 14-day assessment

    Short-term pretreatment with deferoxamine enhances the in vivo vascularization capacity of nanofat seeded onto dermal substitutes

    EXCLI journal

Functional microvessel density

upin mice1

1 study
  1. Deferoxamine increases functional microvessel density in mice.

    “a significantly higher functional microvessel density in both implant border and center zones when compared to controls.”

    Animalsnanofat seeded onto collagen-glycosaminoglycan-based dermal substitutes; compared with vehicle pretreatmentex vivo nanofat pretreatmentdermal substitute implant border and center zones1 mM1 h pretreatment; 14-day assessment

    Short-term pretreatment with deferoxamine enhances the in vivo vascularization capacity of nanofat seeded onto dermal substitutes

    EXCLI journal

All 47

Has deferoxamine been tested in people?

0 of 28 about aging

Yes: 6 observational studies in people have been published, and 28 trials are registered.

Approved

  • FDA Desferal

    Apr 1, 1968Iron Overload, transfusional iron overload

Repurposing

All 22

In trials

  • Cardiac iron overload

    Phase 2Results posted2 trials

  • Transfusion dependent beta thalassemia patient

    Phase 2Terminated1 trial

  • Triple negative breast neoplasm

    Phase 2Terminated1 trial

  • Hepatocellular carcinoma non resectable

    Phase 1Status unknown1 trial

Stopped

  • NCT01459718TerminatedCardiac iron overload

    The study terminated due to low enrollment.

  • NCT05300958TerminatedTriple negative breast neoplasm

    Difficulty accruing subjects the study accrual was closed.

Trial sponsors

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 6Jan 2026: 2Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 3Jun 2026: 0Jul 2026: 2Aug 2026: 1Sep 2026: 0Oct 2026: 1Nov 2026: 117 papers in 12 months
Research Square

Silencing LCN2 eases postoperative cognitive deficits in mice

AAV-mediated knockdown of LCN2 in aged mice limited microglial inflammation, reduced neuronal pyroptosis, and rescued memory following surgery.AAV-mediated knockdown of LCN2 in aged mice limited microglial inflammation, reduced neuronal pyroptosis, and rescued memory following surgery.

Preprint: experiments in miceLCN2

See all 45 papers on deferoxamine